Childhood pre-B cell acute lymphoblastic leukemia (pre-B ALL) can frequently be traced to a pre-leukemic clone carrying a genetic lesion that was acquired in utero (for example, ETV6-RUNX1) 1,2 . During early childhood, pre-leukemic clones can acquire secondary mutations and evolve toward overt leukemia 3 . Leukemia cells follow Darwinian trajectories of clonal evolution, in which sequentially acquired genetic lesions increase or decrease the adaptive fitness of pre-leukemic clones, which results in their positive or negative selection 4 . While this concept is well established, the mechanism(s) that drive(s) clonal evolution is (are) not known. Epidemiological studies have suggested a model of clonal evolution that is driven by recurrent infections during childhood [4] [5] [6] [7] [8] . It has been hypothesized that delayed exposure of infants to infections in the highly protective environments of developed societies causes protracted and excessive immune responses with substantial collateral damage 6, 8 . Early exposure to common infections (such as via attendance at a daycare facility) mitigates this risk 5, 8 . The systematic introduction of vaccination programs during early childhood has reduced the incidence of ALL, presumably by reducing chronic infections and the immune responses that they instigate 7 . For example, the administration of vaccine against Haemophilus influenzae type b in early childhood significantly reduced the risk of childhood ALL in three different case-control studies of American, Finnish and Canadian cohorts 9-11 .
A r t i c l e s
Childhood pre-B cell acute lymphoblastic leukemia (pre-B ALL) can frequently be traced to a pre-leukemic clone carrying a genetic lesion that was acquired in utero (for example, ETV6-RUNX1) 1, 2 . During early childhood, pre-leukemic clones can acquire secondary mutations and evolve toward overt leukemia 3 . Leukemia cells follow Darwinian trajectories of clonal evolution, in which sequentially acquired genetic lesions increase or decrease the adaptive fitness of pre-leukemic clones, which results in their positive or negative selection 4 . While this concept is well established, the mechanism(s) that drive(s) clonal evolution is (are) not known. Epidemiological studies have suggested a model of clonal evolution that is driven by recurrent infections during childhood [4] [5] [6] [7] [8] . It has been hypothesized that delayed exposure of infants to infections in the highly protective environments of developed societies causes protracted and excessive immune responses with substantial collateral damage 6, 8 . Early exposure to common infections (such as via attendance at a daycare facility) mitigates this risk 5, 8 . The systematic introduction of vaccination programs during early childhood has reduced the incidence of ALL, presumably by reducing chronic infections and the immune responses that they instigate 7 . For example, the administration of vaccine against Haemophilus influenzae type b in early childhood significantly reduced the risk of childhood ALL in three different case-control studies of American, Finnish and Canadian cohorts [9] [10] [11] .
Altered cytokine environments in the context of inflammation eliminate multiple normal pre-B cell clones from the repertoire and favor the selective outgrowth of pre-B cell clones that already harbor a preleukemic genetic lesion, such as ETV6-RUNX1 (ref. 12 ). ETV6-RUNX1 was identified as a prenatally acquired genetic rearrangement 13 . Additional postnatally acquired lesions over the course of up to 15 years can give rise to leukemia in the subgroup of patients carrying the ETV6-RUNX1 lesion. While ETV6-RUNX1 is frequently found in umbilical cord B cells and neonatal Guthrie blood spots 13 , less than 1% of newborn children carrying ETV6-RUNX1 eventually develop ALL 14 . Such studies have led to the idea that persistent infection and delayed exposure to strong inflammatory stimuli in childhood may increase the risk of acquiring the post-natal genetic lesions. However, the mechanistic basis of how such pre-leukemic clones evolve has remained elusive.
Two classes of enzymes are required for the somatic recombination and mutation of immunoglobulin-encoding genes in B cells: the proteins encoded by recombination-activating genes (RAG1 and RAG2) introduce DNA double-strand breaks and recombine segments encoding the variable (V), diversity (D) and joining (J) regions 15 ; and AID deaminates cytosine residues in immunoglobulin V and switch regions and thereby enables somatic hypermutation (SHM) and class-switch recombination (CSR) of immunoglobulinencoding genes 16 . We note that genetic diversification of antibodies A r t i c l e s by AID and RAG1-RAG2 is activated in response to infectious and inflammatory stimuli, both in early B cells 17 and in mature B cells 18 . A comprehensive breakpoint analysis 19 has suggested that some chromosomal rearrangements in human B cell malignancies may result from cooperation between RAG1-RAG2 and AID. During normal B cell development, however, the enzymatic activities of these proteins are normally strictly segregated 20 .
Here we report that the enzymes noted above not only genetically diversified the B lymphocyte repertoire 21 but also contributed to the acquisition of genetic lesions and promoted clonal evolution toward leukemia. We also delineate the molecular mechanism by which the normal physiological process of antibody diversification is subverted in pre-leukemic B cell clones (ETV6-RUNX1), leading to overt disease.
RESULTS
Genes frequently deleted in childhood ALL are targets of AID RAG1 and RAG2 are constitutively expressed in pro-and pre-B cells and target recombination signal sequences in both genes encoding immunoglobulins and those that do not encode immunoglobulins. Motif analyses of deletion breakpoints in the tumor suppressorencoding genes IKZF1 (ref. 22) , CRLF2, TBL1XR1, CDKN2A, NR3C1, NR3C2 and BTG1 (ref. 23 ) has revealed that the recombination signal sequence motifs in these genes are indeed targeted by RAG1-RAG2.
To test the plausibility of the contribution of AID to RAG1-RAG2-mediated deletions and rearrangements, we assessed whether lesions in childhood ALL (data from the Children's Oncology Group (COG) clinical trial P9906) occur 'preferentially' at genes bound by AID in normal B cells. We identified 40 genes that were recurrently mutated, deleted or rearranged in childhood ALL (207 patients in trial P9906) and plotted the frequency of these lesions relative to the targeting of these genes by mouse AID (mAID) in mouse B cells. 4,167 mAID-target genes were identified in a published study by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq), on the basis of a greater number of mAID ChIP-seq tags in Aicda +/+ B cells than in AID-deficient (Aicda −/− ) B cells 24 . 18,248 genes that were not targets of mAID did not have significantly higher mAID ChIP-seq tag counts in Aicda +/+ B cells than in than in Aicda −/− B cells 24 . Notably, the frequency of recurrent genetic lesions correlated significantly with mAID ChIP-seq counts (Fig. 1a) . In this analysis, 34 of 40 genes with recurrent lesions in childhood ALL were targets of mAID, which indicated a possible contribution of AID to frequent genetic lesions in childhood ALL. Of the remaining 6 genes that were not targets of mAID, 5 (CDKN2A, TBL1XR1, NR3C1, NR3C2 and PBX1) 23, 25 have breakpoints at known recombination signal sequence motifs with characteristic N-nucleotide addition at the break junctions, which suggests that the lesions at these loci were caused by RAG1-RAG2 activity alone. We note that not all targets of AID are syntenic between humans and mice. While this represents a limitation to our approach, disparity between targets of AID in humans and mice will only lead to an underestimation of the correlation we observed. Moreover, a published study identifying targets of human AID in B cell lymphoma 26 , although not quantitative, includes various genes from our analysis (PAX5, BTG1, BTG2, BACH2, RHOH, EBF1 and TCF3). These studies confirmed that AID might be responsible for mutating a substantial percentage of the genes frequently found to be altered in pre-B ALL.
Abundant AICDA and RAG1 mRNA indicates poor ALL outcome If AID allows clonal evolution toward childhood ALL, its expression and activity might correlate with clinical outcomes of patients. To test this possibility, we correlated AICDA mRNA expression in patients at diagnosis with overall and relapse-free survival. We segregated patients with ALL in two clinical trials (Eastern Cooperative Oncology Group (ECOG) trial E2993 and COG trial P9906) into two groups on the basis of AICDA mRNA abundance at the time of diagnosis that was higher or lower than the median. The ECOG E2993 trial included 215 patients (106 bone marrow samples and 109 peripheral blood samples), and the COG P9906 trial had 207 pediatric patients (131 bone marrow samples and 76 peripheral blood samples).
Notably, higher-than-median AICDA expression was strongly indicative of poor overall patient survival (P = 0.026; Supplementary  Fig. 1a, left) . Likewise, higher-than-median RAG1 mRNA abundance was indicative of shorter relapse-free and overall survival of patients Supplementary Fig. 1a, center and right) . In the COG P9906 trial, 49 patients relapsed after successful initial therapy. In a comparison of AICDA mRNA expression in matched sample pairs at diagnosis and relapse, for most patients, AICDA mRNA abundance was increased at relapse (Supplementary Fig. 1b) . These findings suggested that AICDA expression at diagnosis can be used to predict the outcome of patients with ALL.
RAG and AID proteins are active in precursors of human B cells Pre-B ALL arises from sites of early B lymphopoiesis (fetal liver and bone marrow) during prenatal development and postnatal development, respectively. RAG enzymes are active in precursors of B cells in both sites. Studies of identical twins with concordant ETV6-RUNX1 lesions pre-B ALL have indicated clonal origin of cells undergoing RAG-dependent rearrangement of the immunoglobulin heavy-chain locus (IGH) V region and continued recombinant activity during subsequent clonal evolution 13, 27 . To measure AID activity in precursors of human fetal liver and bone marrow B cells, we sorted CD19 + pre-B cells lacking κ-and λ-chains (immunoglobulin light chains) from liver tissues of three fetal donors and bone marrow of one healthy adult donor. We then cloned and sequenced the IGH V regions (V H ) to assess SHM and cloned and sequenced the IGH constant regions (C H ) to assess CSR ( Supplementary Tables 1 and 2) . Notably, most bone marrow pre-B cell clones expressed IGH with mutated V H regions (with a frequency of 26 mutations per 10 3 base pairs (bp); Fig. 1b Table 2 ). To control for errors induced by reverse transcriptase and Pfu DNA polymerase, we sorted CD3 + T cells lacking AICDA expression from peripheral blood, amplified rearranged V regions from genes encoding the T cell antigen receptor (TCR) β-chain (TCRB) and γ-chain (TCRG) and analyzed these in parallel with IGH V H regions of bone marrow and fetal liver pre-B cells. Overall, IGH V H regions in sorted bone marrow and fetal liver pre-B cells carried a significantly greater frequency of somatic mutations than did the TCRB and TCRG V regions in peripheral blood T lymphocytes (Fig. 1b) . We also found that a fraction of the sorted CD19 + pre-B cells sorted from fetal liver tissues expressed class-switched IGH and contained C γ 3, C γ 1 and C α regions (Fig. 1b,c and Supplementary Table 2 ). We note that our method of IGH cloning and sequencing was not strictly quantitative. Therefore, we were not able to predict the exact fraction of fetal liver pre-B cells that expressed class-switched IGH C regions. These findings suggested that AID might be prematurely activated in human bone marrow and fetal liver pre-B cells. While we found genetic traces of AID activity in RAG1-RAG2-expressing pre-B cells, these findings did not establish concurrent activity of AID and RAG1-RAG2 in the same cells.
Small pre-BII cells have increased genetic vulnerability
To elucidate whether and how premature activity of mAID is regulated during early B lymphopoiesis, we sorted B cell precursors from normal mouse bone marrow as described 20 by flow cytometry. We isolated pro-B cells (c-Kit + B220 + ), large pre-BII cells (CD25 + B220 + FSC hi SSC lo ) and small pre-BII (CD25 + B220 + FSC lo SSC lo ). As large and small pre-BII cells carry similar surface markers, we used their size differences (forward scatter (FSC)) to separate them. We then measured npg the abundance of Aicda mRNA in each fraction of early B cell development (Fig. 2a) . Aicda mRNA was generally less abundant in (or absent from) bone marrow precursors of B cells than in activated mature splenic B cells (Fig. 2a) . However, Aicda mRNA was ~21-fold more abundant at the small pre-BII cell than at the large pre-BII cell stage of early B lymphopoiesis (Fig. 2a) . This transition is characterized by signals from the pre-B cell antigen receptor (pre-BCR) and its intracellular signaling components that are assembled by the pre-BCR linker BLNK 28, 29 . One consequence of pre-BCR signaling at the transition from large pre-BII cell to small pre-BII cell was downregulation of surface expression of the interleukin 7 receptor α-chain (IL-7Rα) by activation of BLNK (Fig. 2b) . Attenuation of IL-7R expression dephosphorylates and inactivates the signal transducer STAT5 in small pre-BII cells 30 . Therefore, to investigate whether the abundance of Aicda mRNA was increased in small pre-BII cells, we abrogated IL-7R-STAT5 signaling via two methods. First, we reconstituted BLNK in Blnk −/− pre-B cells to induce downregulation of IL-7R expression and measured the abundance of Aicda mRNA ( Supplementary  Fig. 2a ) and mAID protein (Fig. 2c) . Second, we removed IL-7 from pre-B cell cultures ( Fig. 2d and Supplementary Fig. 2b ) to force transition from the large pre-BII cell stage to the small pre-BII cell stage.
In vitro differentiation by each method induced upregulation of mAID protein expression, which demonstrated that active IL-7R signaling in mouse large pre-BII cells served as a safeguard against premature mAID expression.
IL-7R safeguards human pre-B cells against AID activation
We next investigated whether IL-7R signaling protects human pre-B cells from premature AID expression. While IL-7R signaling is essential for B cell development in mice, humans with inherited IL7R deficiency have almost normal B cell counts 31 , which allows experimental analysis of human B lymphopoiesis in the absence of IL-7R signaling.
We isolated large and small pre-BII cells from bone marrow samples of three patients with biallelic germline mutations in either gene encoding IL-7R (IL7R and IL2RG) that result in a lack of functional IL-7R signaling. One patient harbored a mutation in IL7R resulting in a G28X substitution in IL-7R; the two other patients each carried a mutation in IL2RG resulting in a Q144X or R289X substitution in IL-7R (Fig. 2e) . As a control, we studied large and small pre-BII cells sorted from the bone marrow of three healthy donors. As in mouse B lymphopoiesis, we observed that human pre-B cells upregulated AICDA mRNA by 10-to 25-fold at the transition from the large pre-BII cell stage to the small pre-BII cell stage (Fig. 2e) . The pre-B cells from the three patients lacking functional IL-7R signaling expressed more AICDA mRNA than did those from the healthy control subjects (Fig. 2e) . We observed no significant difference between large pre-BII cell subset and small pre-BII cell subset from IL-7R-deficient patients in their abundance of AICDA mRNA (Fig. 2e) . Amplification and sequencing of IGH V H regions revealed a low frequency of SHM in small pre-BII cells from healthy control subjects (Fig. 2e) . The frequency of somatic mutations in the IGH V H region was about fivefold higher in both large pre-BII cells and small pre-BII cells of patients lacking functional IL-7R than in those from healthy control subjects (Fig. 2e) . Thus, IL-7R served as a safeguard against premature activation of AID in human pre-B cells.
Safeguard mechanism of IL-7R against AID activation IL-7R-STAT5 signaling in early pre-B cells 32 
A r t i c l e s
Stat5a and Stat5b in large pre-BII cells resulted in the upregulation of AID expression (Fig. 3a) . We assessed the mechanistic role of AktFoxo1 signaling in regulating the abundance of Aicda mRNA through the use of genetic loss of function of PTEN, a negative regulator of Akt, and gain-of-function studies of Foxo1. Inducible deletion of Pten results in hyperactivation of Akt and, hence, phosphorylation and inactivation of Foxo transcription factors 35 . Pre-BCR signaling via BLNK not only decreased the surface expression of IL-7R (Fig. 2b) but also caused activation of Foxo factors 35 such as Foxo4 (Fig. 3b) . Cremediated inducible ablation of Pten caused nearly complete loss of the expression of Rag1, Rag2 and Aicda mRNA (Fig. 3c-e) . In agreement with those findings, a constitutively active form of Foxo1 that is protected from Akt-mediated phosphorylation substantially activated the transcription of Rag1, Rag2 and Aicda (Fig. 3f-h) . Notably, these effects were further enhanced by removal of IL-7 from the cell culture medium, to elicit differentiation into small pre-BII cells (Fig. 3f-h and Supplementary Fig. 2d ). In summary, IL-7R signaling protected pre-B cells from premature expression of Aicda through STAT5-and Akt-dependent pathways.
Concurrent RAG and AID activity in pre-B cell clones AID expression is upregulated in mature B cells upon antigen encounter in germinal center, where it introduces SHM in Igh V H regions and promotes CSR of C H regions 16, 36 . Antigen encounter in germinal centers can be mimicked by the treatment of mature splenic B cells with lipopolysaccharide (LPS) and IL-4. We investigated whether small pre-BII cells respond to inflammatory agents such as LPS in a manner similar to that of mature B cells, by upregulating mAID expression.
To measure such expression of mAID in pre-B cells at the single-cell level, we studied pre-B cells from an Aicda-GFP reporter mouse strain in which the gene encoding green fluorescent protein (GFP) is fused in-frame to exon 5 of Aicda (Aicda-GFP mice, which produce mAID-GFP) 37 . We propagated Aicda-GFP pre-B cells in IL-7 and then left the cells untreated or treated them with LPS, in the continued presence or withdrawal of IL-7. Treatment with LPS induced a minimal increase in mAID expression ( Fig. 4a and Supplementary Fig. 3a,b) . However, combined treatment with LPS plus withdrawal of IL-7 resulted in 20-fold greater upregulation of mAID expression than did treatment with LPS in the presence of IL-7 (Fig. 4a,b) . To measure the expression of mAID and activity of RAG1-RAG2 in parallel at the single-cell level, we monitored mAID-GFP and de novo surface expression of immunoglobulin κ-light chains after RAG-mediated rearrangement of V κ -J κ gene segments. Treatment of Aicda-GFP pre-B cells with LPS in the presence of IL-7 induced activation of the Aicda-GFP reporter in 2.8% of cells, compared with its activation in 0.01% in the condition without LPS treatment ( Fig. 4a and Supplementary Fig. 3b) . However, the combination of treatment with LPS plus with removal of IL-7 from the cell culture medium increased the fraction of mAID-expressing cells to 42%, from 2.8% in the presence of IL-7 ( Fig. 4a and Supplementary  Fig. 3b) . Notably, the majority of Aicda-GFP cells also had de novo expression of κ-light chains ( Fig. 4a and Supplementary Fig. 3b) , which provided direct evidence that mAID expression and RAGmediated recombination of V κ and J κ gene segments occurred in the same cells. We confirmed those findings in a second Aicda reporter mouse model, in which mAID drives expression of Cre for excision of a loxP-flanked 'stop' cassette encoding an enhanced yellow fluorescent protein marker, located in the ubiquitous Rosa26 locus 37 ( Supplementary Fig. 3c,d) . A r t i c l e s sequential RAG-mediated V H replacement 38 . We present here the process of leukemic clonal evolution by cooperative activities of AID (SHM) and the RAG recombinase (V H replacement) in a pediatric patient with pre-B ALL ( Supplementary Fig. 4 and Supplementary Table 5 ). Comparing mutation frequencies in V H and J H gene segments, we found that J H gene segments carried a significantly higher load of somatic mutations (102 per 10 3 bp (J H ) versus 16 per 10 3 bp (V H ); P = 0.0007; Fig. 4c and Supplementary Tables 3-5 ). Multiple rounds of V H replacement, during which acquired mutations in V H segments are erased but D-J H junctions remain constant, could explain this unexpected difference. In 7 of 13 patients with pre-B ALL with the ETV6-RUNX1 lesion, we found multiple distinct subclones that had undergone V H replacement (Supplementary Table 3) , which suggested that RAG enzymes were particularly active in this subset. This finding was in agreement with a study highlighting aberrant activation of RAG-mediated recombination as the primary driver of ETV6-RUNX1 leukemogenesis 23 . To determine if ETV6-RUNX1 activity is linked to deregulated RAG expression, we transduced mouse pre-B cells with vector encoding full-length ETV6-RUNX1 or mutant ETV6-RUNX1 lacking the DNA-binding runt homology domain, or with empty vector, as a negative control. Notably, full-length ETV6-RUNX1 induced expression of Rag1-Rag2 in mouse pre-B cells, but the mutant ETV6-RUNX1 lacking the DNA-binding domain did not (Fig. 4d,e) ; this suggested that the abnormally high recombinase activity in this ALL subset was caused by the ETV6-RUNX1 fusion. Hence, cooperative AID and RAG activities might explain the mechanism of clonal evolution in ETV6-RUNX1 leukemias.
Enrichment for cytosine deamination of CpG in patients with ALL As the targets of AID are frequently deleted or mutated in childhood ALL, we analyzed mutational 'hot-spot' targeting in samples derived from 24 patients with ALL: 10 with the ETV6-RUNX1 lesion, 4 with the MLL-AF4 lesion, 1 with the TCF3-PBX1 lesion, and 9 lacking a recurrent chromosomal translocation (Supplementary Table 6 ; mutation data not shown). In agreement with two published studies 23, 39 , whole-exome sequencing revealed substantial enrichment for C-to-T transitions at CpG dinucleotides, which accounted for 44% of all substitutions. Cytosine deamination at methylated CpG dinucleotides indicates the involvement of AID-mediated deamination of methylated CpG 19 . However, in agreement with published studies 23, 38 , somatic mutations in samples from human subjects with ALL did not reveal the typical hot-spot targeting described for SHM of IGH V H gene segments (such as the DNA sequences RGYW or WRCY, where 'R' indicates A or G, 'Y' indicates C or T, and 'W' indicates A or T) 40 . The targeting of hot spots by AID typically emerges from a large number of somatic mutations in IGH V H gene segments that were non-productively rearranged; hence, the mutations do not affect the outcome of clonal selection among B cells. The mutations in genes not encoding immunoglobulins in the cells from subjects with ALL studied here occurred at much lower frequencies and in coding regions, which left open the possibility that hot-spot targeting had been obscured by low mutation frequencies and effects of clonal selection.
Coordinate AID-RAG activity subverts genetic integrity in B cells
On the basis of our findings reported above, we propose that premature AID expression in small pre-BII cells represents a vulnerability that exposes early B lymphocyte development to genetic lesions in the context of repeated exposure to inflammatory stimuli ( Supplementary  Fig. 5 ). We therefore assessed the relevance of the cooperation of RAG and AID in clonal evolution in normal cord blood-derived human B cells through a genetic gain-of-function experiment. We sorted CD19 + B cells from human cord blood and immortalized the cells through treatment with supernatants of B95-8 marmoset B cell cultures containing Epstein-Barr virus (EBV). We then transduced the proliferating cord blood B cells with vector encoding AID tagged with the red fluorescent protein iRFP670, RAG1 tagged with enhanced greed fluorescent protein (eGFP), or RAG2 tagged with the red fluorescent protein dsRedE2, either alone or in combination, or emptyvector controls for the AID, RAG1 and RAG2 vectors (Fig. 5a,b and Supplementary Figs. 6 and 7) . We sorted transduced cord blood B cells in each condition and confirmed by immunoblot analysis the expression of AID, RAG1 and RAG2 (or lack thereof) (Fig. 5a) . Our finding that AID expression was absent in EBV-infected B cells was consistent with published literature. EBV suppresses AID expression 41 To be able to study genetic lesions at the level of individual clones, we plated single transduced human B cell clones into individual wells of 96-well plates. We harvested cord blood B cell clones and subjected them to whole-exome sequencing. We analyzed EBV-immortalized cord blood B cells carrying three empty-vector controls (iRFP670, eGFP and dsRedE2); vector encoding AID and two empty vector controls; vectors encoding RAG1 and RAG2 and one empty vector control; or vectors encoding AID, RAG1 and RAG2. This analysis focused on the following structural genetic lesions: insertions, deletions, inversions and translocations. Cells with overexpression of either AID alone or RAG1-RAG2 had only a greater frequency of interchromosomal translocations than did cord blood B cells transduced with empty-vector controls (Fig. 5c) . However, cord blood B cells expressing AID in combination with RAG1-RAG2 had a greater absolute number of insertions, deletions, inversions and intrachromosomal translocations than did cord blood B cells transduced with empty-vector controls (Fig. 5c) .
RAG1-RAG2 and AID act together in ETV6-RUNX1 leukemia
We hypothesized that AID and RAG1-RAG2 would act together and induce secondary genetic lesions to accelerate the leukemogenesis of an ETV6-RUNX1 small pre-BII clone in the context of inflammation. To test this, we transduced pre-B cells from wild-type (Aicda +/+ Rag1 +/+ ), Aicda −/− Rag1 +/+ and Aicda +/+ Rag1 −/− mice with ETV6-RUNX1 and subjected them to five rounds of withdrawal of IL-7 and treatment with LPS. During each cycle, a large fraction of stimulated pre-B cells died (data not shown). Before entering the next round of stimulation, the pre-B cells among a small fraction of surviving pre-B cells recovered over the course of ~2 weeks (data not shown). The cell death after each cycle occurred independently of the Aicda or Rag1 genotype (data not shown). This was not unexpected, because withdrawal of IL-7 induces many AID-and RAG1-RAG2-independent signaling pathways that promote apoptosis at the small pre-BII cell stage of B lymphopoiesis.
After five cycles of treatment as described above, we labeled the treated pre-B cells, as well as their untreated counterparts that did not undergo IL-7 withdrawal or treatment with LPS, with firefly luciferase and injected the cells intravenously into mice of the non-obese diabetic (NOD) severe combined immunodeficiency (SCID) strain (Fig. 6a) . All mice that received wild-type (Aicda +/+ Rag1 +/+ ) pre-B cells died of leukemia within 3 weeks (Fig. 6b) . We killed three to four mice in that same group that received wild-type (Aicda +/+ Rag1 +/+ ) pre-B cells at the same time because they were terminally ill with leukemia. This phenomenon was reflected in the rapid decrease in the Kaplan-Meier survival curve for this group (Fig. 6b) . In contrast, the absence of Aicda or Rag1 delayed or abrogated, respectively, the development of leukemia (Fig. 6a,b and Supplementary Figs. 8 and 9) , which demonstrated that both AID and RAG1 were required for the clonal evolution of ETV6-RUNX1 pre-B cells toward leukemia. In the absence of Aicda, two mice developed leukemia, albeit after a substantially prolonged latency period (Fig. 6b) . We were able to verify that the sick mice given injection of wild-type (Aicda +/+ Rag1 +/+ ) pre-B cells that had been stimulated by withdrawal of IL-7 plus treatment with LPS indeed died of pre-B ALL ( Fig. 6c and Supplementary  Figs. 8 and 9 ). These findings provided genetic evidence that the clonal evolution of pre-leukemic ETV6-RUNX1 pre-B cells in the context of inflammatory and/or repetitive infectious stimulation required the activity of both AID and the RAG recombinase.
DISCUSSION
A published study has demonstrated that aberrant RAG-mediated V(D)J recombination targeting genes not encoding immunoglobulins causes genetic lesions that drive the clonal evolution of pre-B ALL 23 . Likewise, AID targets such genes, promotes drug resistance in B lineage ALL 43, 44 and gives rise to AID-dependent chromosomal rearrangements. A comprehensive sequence analysis of 1,700 breakpoints of chromosomal rearrangements in human B cell malignancies has suggested that these lesions are caused by cooperation between the RAG recombinase and AID 19 . That conclusion was based on the unexpected finding that ~70% of chromosomal rearrangements in pro-and pre-B cells involve a break at CpG dinucleotides. Cytosine residues in CpG dinucleotides are frequently methylated. While AIDmediated deamination of cytosine typically results in conversion to uracil and triggers highly efficient base-excision repair, AID-mediated deamination of methylated cytosine (for example, in CpG) results in the conversion of cytosine to thymine. The resulting T:G mismatch is more stable than a U:G mismatch, and repair of T:G mismatches is ~2,500 times less efficient than that of U:G mismatches 45 . These T:G mismatches generate a one-base 'bubble' that is recognized by the RAG recombinase, which results in the introduction of a singlestrand nick 19 . AID thus generates multiple one-base 'bubbles' (T:G mismatches) at methylated CpG sequences that form substrates for RAG-mediated cleavage. An important premise for this scenario is that under some circumstances, B cells express RAG proteins and AID concomitantly. Our findings have highlighted the observation that small pre-BII cells represented a subset of increased genetic vulnerability because they concurrently expressed AID and RAG1-RAG2 in the presence of strong inflammatory stimuli. The concurrent activation of these enzymes would provide an explanation for the thus-far-elusive origin of childhood leukemia. We have formally demonstrated that combined activities of AID and the RAG recombinase were required for clonal evolution from pre-leukemic lesions and that such cooperative activities potentiated genetic instability in these clones. We elucidated how IL-7R signaling served as a safeguard protecting the early B cell genome from premature expression of AID. Altered cytokine environments have been previously attributed to the clonal evolution of ETV6-RUNX1-driven pre-B ALLs 12 . Here we have provided one more example of this phenomenon by which cytokine signaling in pre-B cells can contribute to genomic stability and, hence, leukemic transformation.
Our work provides a mechanistic underpinning for the epidemiological findings that altered patterns of infection during early childhood provide a promotional drive to leukemogenesis, especially for subtypes of childhood leukemia initiated in utero via ETV6-RUNX1 fusion or hyperdiploidy 6 . In the future, it may be useful to investigate whether leukemic children with known infectious origins have high expression of AID and RAG enzymes. It might also be important to identify the classes of pathogens responsible for overt leukemogenesis in such children. Delineation of the molecular bases of the infectious and inflammatory origins of pre-B ALL could inform the development of public health policies on the benefits of vaccination programs during early childhood for the prevention of leukemia.
METHODS
Methods and any associated references are available in the online version of the paper. 
